Last month the Australian Pharmaceutical Benefits Advisory Committee cleared antiretroviral drug Pre-exposure prophylaxis (PrEP), the once-daily tablet used to protect HIV negative people from infection, for listing on the Pharmaceutical Benefits Scheme (PBS).
Today, Federal Health Minister Greg Hunt announced that PrEP will be available publicly on the scheme from April 1.
The Australian government will contribute $180 million in subsidy for the drug of which Hunt explained, “puts Australia in reach of being one of the first countries in the world to end the transmission of HIV”.
Without the subsidy, and if a person was not part of part of one of the state clinical trials in either NSW, Victoria, South Australia or Queensland, prescriptions cost around $208 per monthly script for PrEP – $2496 per year. The subsidy reduced the cost will see prescriptions costing $39.50 per script.